Attendees at the American Society for Microbiology (ASM) Microbe 2024 in Atlanta, Georgia are invited to view three posters presented by Microbio Founder and Chief Scientific Officer, Dr Flavia Huygens. If you’re curious about the power of molecular diagnostics to support clinical decision-making in sepsis, a discussion with Dr Huygens is highly recommended! đź’ˇFriday 14… Continue reading ASM Microbe 2024: How molecular diagnostic tests can inform clinical decision-making
Category: Blog post
Introducing Microbio
Microbio is an Australian biotech startup that plans to change the course of pathogen detection. Our novel diagnostic method combines the latest advances in bioinformatics, genomics and molecular microbiology to deliver rapid pathogen detection using qPCR. Developed in collaboration with Australian clinicians, Microbio’s flagship product InfectID-BSI has been designed with clinical decision-making in mind, to… Continue reading Introducing Microbio
Microbio appoints Colin Keating as CEO
Brisbane, 24 October 2023 – Microbio Ltd, an Australian molecular pathogen diagnostics company, is pleased to announce the appointment of Colin Keating as CEO, effective from 1 November 2023. Mr Keating joined Microbio as interim COO in May and assumed the role of interim CEO in early June. Mr Keating’s experience delivering transformation programs at… Continue reading Microbio appoints Colin Keating as CEO
Microbio Shareholder Rights to Receive Documents
Microbio Shareholder Notice of Rights to Receive Documents
September is Sepsis Awareness Month
Every September the world marks Sepsis Awareness Month. This year Microbio celebrates the incredible work undertaken by sepsis organisations around the world, who are raising awareness, advocating for survivors and improving sepsis management. Follow us on LinkedIn and X to find out the latest statistics, learn the signs and read the stories of sepsis patients… Continue reading September is Sepsis Awareness Month